NateraNTRA
Recorded

Natera 2026 UBS Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration37 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

All right. Good morning, everybody. Thank you for joining us. On behalf of UBS, first off, I'm Doug Schenkel, just in case you don't know, and it's my pleasure on behalf of UBS to welcome Mike Brophy, CFO of Natera. Michael, thank you for being here.

Mike BrophyCFO

Oh, thanks for having me. Good to see you guys.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Looking around the room, I think most of you know Natera, but I think it's important to just set the stage by acknowledging the journey you've been on, where you guys have just done a remarkable job establishing a leadership position in reproductive health, and then moving into MRD. I mean, there's not too many companies where you say, at least in our space, you did a really good job in one area, and then you go out and dominate with a second act. You guys have done that in MRD, a market we believe could ultimately represent a $15 billion-$30 billion annual revenue opportunity. You're now pursuing additional indications, adjacencies, and moving into new geographies. We'll tackle a little bit of that today.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

With that in mind, before we get into it, just to provide a roadmap, there were a few developments last week at the company.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Panorama volumes? Panorama volumes is where we are going to start.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

But I definitely want to talk about the CEO announcement, the 2029 framework.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Yeah. Then we will get into the all-important questions about Signatera, adjacencies, geographies, and CRC screening.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

We will see what we can cover over the next half hour. Kicking off on the CEO transition.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Yeah. Maybe tell us about Solomon before we break down how we got here.

Mike BrophyCFO

Yeah. Solomon is the 40th or 41st employee that joined Natera in 2011. There's probably not one single person that's more responsible for the development of these additional areas of focus, first with Prospera in organ health, and then ultimately with Signatera, making the critical choices around what clinical questions to answer, what clinical trials to run, which KOLs to partner with, every decision around product and product strategy for Signatera. Solomon was really the point person for all of that and is obviously critical in the commercial rollout for Signatera. It was a pleasure to listen to Bhavna do the intro for the conference and to have her mention MRD as an industry vertical.

Mike BrophyCFO

Doug and I have done these conferences over the last decade where MRD did not exist as an industry vertical. I'm up here trying to convince people that it ought to be, that this ought to work. It's a pleasure to hear it just mentioned as, of course, it's one of these things that are common and rapidly emerging as a standard of care. Solomon's had a huge role in that. He's worked in each kind of area of the business. He's deeply connected to our R&D teams and our sales teams. I think Natera's a little bit unique in the structure of our leadership team in that we've got a bunch of really long-tenured executives. You mentioned my journey. I've been here 11 years, and I'm the newcomer.

Mike BrophyCFO

Yeah You take a picture of me around 2011 when I first met the company, if you'd taken a picture of us at that first meeting and taken a picture of us at our board meeting this week, it's really all the same people.

Mike BrophyCFO

It's really the same folks, the same core technology, and it's really the same core strategy. We're just a little bit further along. There's a lot of continuity in the handoff between Steve and Solomon. Another thing that's made it a little bit unusual about us is, we're all really dear friends. I know Steve's excited for Solomon. I'm excited for Solomon, and we know he's ready.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Why so abrupt? At least from the outside, it seems like this came out of nowhere.

Mike BrophyCFO

How'd this happen? Yeah, no, I understand from the outside it can be perceived that way.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day